Expression of Multidrug Resistance 1 (MDR1), Multidrug Resistance-related Protein 1 (MRP1), Lung Resistance Protein (LRP), and Breast Cancer Resistance Protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia

International Journal of Hematology

Volumn 86, Issue 2, 2007, Pages 166-173

  Kourti, Maria ^a,c   Vavatsi, N ^a   Gombakis, N ^a   Sidi, V ^b   Tzimagiorgis, G ^a   Papageorgiou, T ^a   Koliouskas, D ^b   Athanassiadou, F ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Aristotle University of Thessaloniki   (Greece)

^c NONE   (Greece)

Author keywords

Acute lymphoblastic leukemia; BCRP; LRP; MDR1; MRP1; Multidrug resistance

Indexed keywords

BETA ACTIN; BREAST CANCER RESISTANCE PROTEIN; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD CELL COUNT; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER RELAPSE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOPHENOTYPING; MALE; MONONUCLEAR CELL; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; INFANT; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDIES; RNA, MESSENGER; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 34548779111     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.E0624     Document Type: Article

References (47)

1. De Moerloose B, Swerts K, Benoit Y, et al. The combined analysis of P-glycoprotein expression and activity predicts outcome in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2003;20:381-391.
2. Kartner N, Ling V. Multidrug resistance in cancer. Sci Am. 1989;260:44-51.
3. Tsuruo T. Mechanisms of multidrug resistance and implications for therapy. Jpn J Cancer Res. 1988;79:285-296.
4. Lautier D, Canitrot Y, Deeley RG, Cole SP. Multidrug resistance mediated by the multidrug resistance protein (MRP) in acute leukemia. Biochem Pharmacol. 1996;52:967-977.
5. Ross DD, Karp JE, Chen TT, Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood. 2000;96:365-368.
6. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat. 2003;6:71-84.
7. Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 1993;53:1475-1479.
8. Scheffer GL, Wijngaard PL, Flens MJ, et al. The drug resistance-related protein LRP is the human major vault protein. Nat Med. 1995;1:578-582.
9. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451-458.
10. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias: European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786.
11. Roy A, Cargill A, Love S, et al. Outcome after first relapse in childhood acute lymphoblastic leukaemia: lessons from the United Kingdom R2 trial. Br J Haematol. 2005;130:67-75.
12. Ogretmen B, Barredo J, Ahmad S. Increased expression of lung resistance-related protein and multidrug resistance-associated protein messenger RNA in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2000;22:45-49.
13. Kourti M, Vavatsi N, Gombakis N, et al. Increased expression of multidrug resistance gene (MDR1) at relapse in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2006;23:489-494.
14. Sauerbrey A, Voigt A, Wittig S, Hafer R, Zintl F. Messenger RNA analysis of the multidrug resistance related protein (MRP1) and the lung resistance protein in de novo and relapsed childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2002;43:875-879.
15. Arceci RJ. Can multidrug resistance mechanisms be modified? Br J Haematol. 2000;110:285-291.
16. Tafuri A, Gregorj C, Petrucci MT, et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood. 2002;100:974-981.
17. Damiani D, Michelutti A, Michieli M, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia. Br J Haematol. 2002;116:519-527.
18. Zochbauer S, Gsur A, Brunner R, Kyrle PA, Lechner K, Pirker R. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia. 1994;8:974-977.
19. Dhooge C, De Moerloose B, Laureys G, et al. Expression of multidrug transporter P-glycoprotein is highly correlated with clinical outcome in childhood acute lymphoblastic leukemia: results of a long-term prospective study. Leuk Lymphoma. 2002;43:309-14.
20. Kanerva J, Tiirikainen MI, Mäkipernaa A, et al. Initial P-glyco-protein expression in childhood acute lymphoblastic leukemia: no evidence of prognostic impact in follow-up. Pediatr Hematol Oncol. 2001;18:27-36.
21. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev. 1990;42:155-199.
22. Goasguen JE, Dossot JM, Fardel O, et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood. 1993;81:2394-2398.
23. Brophy NA, Marie JP, Rojas VA, et al. Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques. Leukemia. 1994;8:327-335.
24. Tafuri A, Sommaggio A, Burba L, et al. Prognostic value of rhodamine-efflux and MDR-1/P-170 expression in childhood acute leukemia. Leuk Res. 1995;19:927-931.
25. Wuchter C, Leonid K, Ruppert V, et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica. 2000;85:711-721.
26. den Boer ML, Pieters R, Kazemier KM, et al. Relationship between major vault protein/LRP, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood. 1998;91:2092-2098.
27. Del Poeta G, Stasi R, Aronica G, et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood. 1996;87:1997-2004.
28. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996;56:3010-3020.
29. Xie XY, Robb D, Chow S, Hedley DW. Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia. Leukemia. 1995;9:1882-1887.
30. Ivy SP, Olshefski RS, Taylor BJ, Patel KM, Reaman GH. Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study. Blood. 1996;88:309-318.
31. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug resistance human lung cancer cell line. Science. 1992;258:1650-1656.
32. Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG, Mehta AB. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukemia. 1994;8:2163-2168.
33. Kakihara T, Tanaka A, Watanabe A, et al. Expression of multidrug resistance-related genes does not contribute to risk factors in newly diagnosed childhood acute lymphoblastic leukemia. Pediatr Int. 1999;41:641-647.
34. Plasschaert SL, Vellenga E, de Bont ES, et al. High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukemic cells in adults than in children. Leuk Lymphoma. 2003;44:85-95.
35. Kickhoefer VA, Rajavel KS, Scheffer GL, Dalton WS, Scheper RJ, Rome LH. Multidrug resistant cancer cell lines contain elevated levels of vaults. Proc Am Assoc Cancer Res. 1997;38:252.
36. List AF, Spier CS, Grogan TM, et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood. 1996;87:2464-2469.
37. Filipits M, Pohl G, Stranzl T, et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood. 1998;91:1508-1513.
38. Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deeley RG, Cole SP. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res. 1993;53:3221-3225.
39. Flens MJ, Izquierdo MA, Scheffer GL, et al. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 1994;54:4557-4563.
40. Slovak ML, Ho JP, Cole SP, et al. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res. 1995;55:4214-4219.
41. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;95:15665-15670.
42. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001;61:3458-3464.
43. Stam RW, van den Heuvel-Eibrink MM, den Boer ML, et al. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Leukemia. 2004;18:78-83.
44. Sauerbrey A, Sell W, Steinbach D, Voigt A, Zintl F. Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukemia. Br J Haematol. 2002;118:147-150.
45. Plasschaert SL, van der Kolk DM, de Bont ES, et al. The role of breast cancer resistance protein in acute lymphoblastic leukemia. Clin Cancer Res. 2003;9:5171-5177.
46. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Sauerbrey A. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia. 2002;16:1443-1447.
47. Den Boer ML, Harms DO, Pieters R, et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol. 2003;21:3262-3268.